Gilead Sciences

Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It
Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It
Forbes
Gilead Sciences
HIV
Truvada
drug ads
Flag link:
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Bloomberg
Express Scripts
PBMs
Gilead Sciences
HIV
Atripla
AbbVie
Mavyret
hepatitis C
Flag link:
China Approves Gilead's Genvoya for HIV-1 Infection
China Approves Gilead's Genvoya for HIV-1 Infection
CP Wire
Gilead Sciences
China
Genvoya
HIV
Flag link:
China Approves Gilead's Genvoya for HIV-1 Infection
Gilead Sciences
Genvoya
HIV
Flag link:
First rumors about Gilead – Vertex or Gilead – Pfizer merger start circulating
First rumors about Gilead – Vertex or Gilead – Pfizer merger start circulating
GoinPharma
Gilead Sciences
Vertex Pharmaceuticals
Pfizer
M&A
Flag link:
Is Gilead Sciences' Sudden Change in Leadership a Good Thing?
Is Gilead Sciences' Sudden Change in Leadership a Good Thing?
Motley Fool
Gilead Sciences
John Martin
John Milligan
Pharma CEOs
Flag link:
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
RAPS.org
Novartis
Merck
GSK
Gilead Sciences
Bayer
AstraZeneca
AbbVie
Takeda
FDA
DDIs
drug-drug interactions
proton pump inhibitors
Flag link:
Gilead CEO John Milligan Stepping Down as Head of Biotech Giant
Gilead CEO John Milligan Stepping Down as Head of Biotech Giant
Bloomberg
Gilead Sciences
John Milligan
Pharma CEOs
Flag link:
Gilead Announces Data on Truvada for HIV Prophylaxis
Gilead Announces Data on Truvada for HIV Prophylaxis
CP Wire
Gilead Sciences
Truvada
HIV
Flag link:
Gilead Announces Data on Truvada for HIV Prophylaxis
Gilead Sciences
HIV
Truvada
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
Yahoo/Zacks.com
Gilead Sciences
earnings
Flag link:
Gilead’s Kite bags option to buy gamma delta startup Gadeta
Gilead’s Kite bags option to buy gamma delta startup Gadeta
Fierce Biotech
Gilead Sciences
Kite Pharma
Gadeta
T-cell receptors
M&A
Flag link:
4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
Motley Fool
HIV
Gilead Sciences
Biktarvy
GSK
Triumeq
Genvoya
Tivicay
Flag link:
3 Biotech Stocks With Big News Coming in NASH
3 Biotech Stocks With Big News Coming in NASH
Motley Fool
NASH
Viking Therapeutics
Gilead Sciences
Intercept Pharma
VK2809
Ocalivia
selonsertib
Flag link:
Pharmas call off price hikes after California law forces new warnings: report
Pharmas call off price hikes after California law forces new warnings: report
Fierce Pharma
drug pricing
California
Novo Nordisk
Roche
Novartis
Gilead Sciences
Flag link:
Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales
Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales
Fierce Pharma
Gilead Sciences
CAR-T
Eisai
Flag link:
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Flag link:
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma
CP Wire
Kite Pharma
Gilead Sciences
EMA
CHMP
Yescarta
B-cell lymphoma
Flag link:
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Yahoo/Reuters
GSK
Gilead Sciences
HIV
AIDS
Dolutegravir
lamivudine
Biktarvy
Flag link:

Pages